11:45 AM EST, 01/13/2025 (MT Newswires) -- Greenwich LifeSciences ( GLSI ) said Monday it has partnered with Unicancer and its breast cancer group to activate clinical sites in France for a phase III clinical trial of the GLSI-100 immunotherapy.

The phase III study of the immunotherapy, which is being evaluated to prevent breast cancer recurrences, will be activated in 19 French sites in the UCBG breast cancer group network, the company said.

Authorities in France approved the sites in Q1 2024, Greenwich said.

Shares were down 1.7% in recent trading.

Price: 12.17, Change: -0.21, Percent Change: -1.70